Company Active LTD

Company profile

Cellular Origins Limited

Home | Cellular Origins

Cellular Origins is building a fully automated, scalable manufacturing solution for cell and gene therapy. Our technology seamlessly integrates production e ...

CRN

13910732

Founded

2022

Age

Overview

Legal name

CELLULAR ORIGINS LIMITED

Region

East of England

Registered address

TTP CAMPUS

CAMBRIDGE ROAD

MELBOURN

UNITED KINGDOM

SG8 6HQ

Insolvency history

Corporate ownership

Updated 06 Jun 2026 16:52

2 levels 1 ultimate controller

Company Active LTD

Cellular Origins Limited

CRN 13910732

Direct controller Active LTD

TTP Group Limited

CRN 02170755

Ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC

TTP Employee Trustee Limited

CRN 13515458

Company events

Reference milestones and recent Companies House filing stream events.

6 events

24 Feb

2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec

2026

Accounts due

Accounts Due

Next accounts due date

10 Feb

2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar

2025

Accounts filed

Accounts

Last accounts made up date

19 Sep

2024

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzQzNjUyODI1NWFkaXF6a2N4 | Paper/PDF filed

Published 20 Sep 2024 11:16

11 Feb

2022

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2025

Funded years

2025

Age at first award

3 years

Projects

2025 Collaborative R&D Lead participant

Realising Full Robotic Automation for Industrial Advanced Therapy Manufacturing; Expanding Constellation Functionality at the Catapult Digital and Automation Test Beds.

1 Jul 2025 to 28 Feb 2027

Awarded

£479,192

Total cost £684,560

Advancements in CGTs for cancer and other high-prevalence conditions are set to transform modern medicine. However, scientific development is outpacing our manufacturing ability to produce these therapies at required scales to reach tens of thousands, let alone millions of eligible patients a year. Current global production (<11,000 therapies/year in 2023...

Product types

Collaborative R&D